Skip to main content
PMC home page
BMC Pulmonary Medicine logoLink to BMC Pulmonary Medicine
. 2019 Oct 22;19:184. doi: 10.1186/s12890-019-0939-y

Functional variations of the TLR4 gene in association with chronic obstructive pulmonary disease and pulmonary tuberculosis

Zhongqi Li 1,#, Xuhua Mao 2,#, Qiao Liu 1, Huan Song 1, Biyu He 1, Peiyi Shi 1, Qun Zhang 3,✉, Xiaona Li 3, Jianming Wang 1,4,✉
PMCID: PMC6805358  PMID: 31640653

Abstract

Objective

Chronic obstructive pulmonary disease (COPD) and pulmonary tuberculosis (PTB) share a number of common risk factors, including innate immunity-related genetic factors. In the present study, we compared the role of genetic variations of the TLR4 gene in susceptibility to COPD and PTB and illuminated the underlying molecular mechanism of functional single-nucleotide polymorphisms (SNPs).

Methods

A population-based case control study was performed in a Chinese Han population and included 152 COPD cases, 1601 PTB cases and 1727 controls. Five SNPs in the TLR4 gene (rs10759932, rs2737190, rs7873784, rs11536889, and rs10983755) were genotyped using TaqMan allelic discrimination technology. We estimated the effects of SNPs using the odds ratio (OR) together with 95% confidence interval (CI). Dual-luciferase reporter vectors expressing different genotypes of SNPs were constructed and transfected into the human HEK 293 T cell line to explore their effects on potential transcription activity.

Results

After Bonferroni correction, the genetic polymorphisms of all five SNPs remained significantly associated with COPD, while rs10759932 and rs2737190 were also associated with PTB. Compared with rs10759932-TT, individuals carrying TC (OR: 0.42, 95% CI: 0.28–0.64) or CC (OR: 0.24, 95% CI: 0.09–0.63) had a significantly reduced risk of COPD. However, individuals carrying TC (OR: 1.28, 95% CI: 1.11–1.49) or CC (OR: 1.26, 95% CI: 0.98–1.62) had an increased risk of PTB. The OR (95% CI) for allele rs10759932-C was 0.45 (0.32–0.62) for COPD and 1.18 (1.07–1.32) for PTB. For rs2737190, heterozygous AG was related to a decreased risk of COPD (OR: 0.32, 95% CI: 0.21–0.49) and an increased risk of PTB (OR: 1.30, 95% CI: 1.11–1.52). The dual-luciferase reporter assay showed decreased transcription activity caused by rs10759932-C and rs2737190-G.

Conclusion

Genetic polymorphisms of rs10759932 and rs2737190 in TLR4 are significantly related to both COPD and PTB but with inverse effects. The altered transcription activity caused by mutations in these two loci may partly explain the observed relationship.

Keywords: Chronic obstructive pulmonary disease, Pulmonary tuberculosis, Toll-like receptor 4, Single nucleotide polymorphism, Genetic

Introduction

Both chronic obstructive pulmonary disease (COPD) and tuberculosis (TB) primarily affect the lungs and are major causes of morbidity and mortality worldwide [1]. COPD is characterized by persistent airflow limitation because of various combinations of obstructive bronchiolitis and emphysema [2, 3]. The airflow limitation is usually not completely reversible and is associated with an abnormal inflammatory response of the lungs exposed to noxious particles and gases [4]. In a current nationwide, cross-sectional survey, the estimated overall prevalence of COPD in China was 13.6% among adults over 40 years old [5]. The etiology of COPD is complicated, and tobacco smoking is considered one of the foremost risk factors [2–4, 6–8]. Other factors, such as pulmonary tuberculosis (PTB), air pollution and low body mass index (BMI), may also contribute to COPD [6, 7]. TB is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) infection, of which PTB is the most common type [9]. In 2017, there was an estimation of 10 million new cases and 1.3 million deaths due to TB worldwide, and the number of new TB cases in China was approximately 889 thousand, making it one of the top 30 countries with high TB burden (www.who.int).

COPD and TB have common risk factors, such as tobacco smoking, malnutrition, low socioeconomic status and dysregulation of host defense functions [1, 10]. Both COPD and TB are characterized by an abnormal innate immune response of alveolar macrophages exposed to both cigarette smoke and Toll-like receptor (TLR) stimulation [11, 12]. Since the first discovery of TLR4 in humans in late 1997, 13 types of TLRs (TLR1-TLR13) have been described in mammals [13]. As an important pattern recognition receptor in the natural immune system, TLR4 serves to discern pathogen-associated molecular pattern (PAMP) molecules or endogenous damage-associated molecular pattern (DAMP) molecules [14, 15]. TLR4 can trigger inflammatory responses by inducing the synthesis and release of proinflammatory cytokines and chemokines. Single nucleotide polymorphisms (SNPs) among various TLR genes have been identified, and their association with susceptibility/resistance to certain infections and other inflammatory diseases has been reported [13]. The interrelationship between COPD and TB is very complex [16]. Growing evidence appears to point towards a bidirectional relationship between these two lung diseases where each may act as an independent risk factor for the other [17]. It appears that the susceptibility of an individual to develop COPD and active TB involves a complex interaction between genetic and environmental factors [16].

Previous studies have reported genetic polymorphisms of TLR4 in association with the risk of COPD and PTB [18, 19], but these two diseases were analyzed independently, and the function of genetic variations was not explored in these studies. In the present study, we compared the effects of genetic variations of the TLR4 gene on the susceptibility to COPD and PTB in a Chinese Han population. Furthermore, we constructed dual-luciferase reporter vectors expressing different genotypes and transfected them into human HEK 293 T cell lines to analyze the potential function of SNPs on the promoter activity of the TLR4 gene.

Materials and methods

Study population and data collection

A total of 152 newly diagnosed COPD cases and 1601 PTB cases were recruited from Jiangsu Province, China from 2011 to 2016. Both COPD and PTB patients included in this study were diagnosed according to the national guidelines. Respiratory function tests were performed for suspected COPD cases using a standard spirometer to measure forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) [20]. The COPD was defined as an FEV1/FVC ratio below 70%. COPD cases with HIV/AIDS, immunosuppressive conditions, active TB, malignancy and other severe respiratory diseases were excluded. PTB cases were diagnosed by specialized doctors following the guidelines recommended by the China Ministry of Health, which were based on clinical symptoms and signs, chest X-ray examination, sputum smear tests or sputum culture (http://www.chinatb.org). PTB cases aged < 18 years, with HIV/AIDS, immunosuppressive conditions, malignancy and other severe respiratory diseases were excluded. All patients were genetically unrelated in the Chinese Han population. We also enrolled 1727 healthy controls who were residents who participated in the local community-based health examination program. They had no history of COPD, TB, HIV/AIDS, immunosuppressive conditions, malignancy or other severe respiratory diseases. After informed consent was obtained, questionnaires were used to collect demographic characteristics, smoking habits, drinking habits and respiratory disease histories. We obtained 3–5 ml venous blood samples from each individual for genetic analysis. This study was approved by the ethics committee of Nanjing Medical University.

SNP selection and genotyping

Five SNPs in the TLR4 gene (rs10759932, rs2737190, rs7873784, rs11536889, rs10983755) were selected for genotyping based on the following criteria: (1) a minor allele frequency ≥ 0.05 in the Chinese Han population; (2) a Hardy-Weinberg equilibrium test P ≥ 0.05; and (3) SNPs located in the functional areas, such as the 5′-UTR or 5′ near the gene, exon or 3′-UTR. The information of these five SNPs is listed in Additional file 1: Table S1. We genotyped the SNPs using the TaqMan allelic discrimination technology on a 384-well ABI 7900HT real-time PCR system (Applied Biosystems, Foster City, CA, USA). Amplification was performed in 0.5 ml tubes, which included 25 μl of premixed Taq version 2.0 (Takara, Kyoto, Japan), 1 μl of 20 μM forward and reverse primers and 100 ng of genomic DNA. The calling rate was over 98%. The primer and probe sequences for each SNP are listed in Additional file 2: Table S2.

Construction of reporter vectors

We obtained − 2588 to + 50 fragments of the TLR4 gene containing rs10759932 (− 1309 T/C) and rs2737190 (− 2272 A/G) through GeneChem Corporation (Shanghai, China). They were named Wt (− 1309 T and − 2272 A), Mut1 (− 1309 C and − 2272 A) and Mut2 (− 1309 T and − 2272 G). PCR was performed to amplify the fragments of Wt, Mut1 and Mut2 in 0.5 ml tubes that included 0.5 μl of PrimeSTAR HS DNA polymerase (Takara), 1 μl of 10 μM forward and reverse primers, 4 μl of 2.5 mM each dNTP Mix (Takara), 10 ng of genomic DNA and 10 μl of 5 × PS Buffer (Takara). The forward primer was designed to contain the KpnI site (underlined): 5′-TTTCTCTATCGATAGGTACCTCGGCTATGGTGAAAACAACAG-3′. The reverse primer was designed to contain the XhoI site (underlined): 5′-CTTAGATCGCAGATCTCGAGGAAGAAAACGCCTGCAGACCAGTG-3′. PCR products and pGL3-basic vectors (Promega, Wisconsin, USA) were double digested with KpnI and XhoI and were ligated with T4 DNA ligase (Takara) to construct dual-luciferase reporter vectors, which were named pGL3-Wt, pGL3-Mut1 and pGL3-Mut2, respectively. The sequencing of recombinant vectors was performed by GeneChem Corporation (Shanghai, China). Figure 1 illustrates the sequence validation of the recombinant vectors (pGL3-Wt, pGL3-Mut1 and pGL3-Mut2).

Fig. 1.

Fig. 1

Open in a new tab

Sequencing of the pGL3 vector. pGL3-Wt: − 1309 T and − 2272 A; pGL3-Mut1: − 1309 C and − 2272 A; pGL3-Mut2: − 1309 T and − 2272 G

Transfection and luciferase assays

Human HEK 293 T cells (GeneChem, Shanghai, China) in the logarithmic growth phase were used for cell suspensions, seeded in 24-well plates (the number of cells was approximately 105), cultured in 37 °C with 5% CO2 and incubated until the fusion degree of cells reached approximately 60%. X-tremegene HP (Roche, Basel, Switzerland) was used for transfection. First, we transfected 1 μg of vectors and 2 μl of X-tremegene HP per well and dissolved X-tremegene HP and vectors in 100 μl opti-MEM (Gibco, Massachusetts, USA) according to this ratio and mixed and incubated them at room temperature for 20 min. Then, we aspirated 300 μl of the culture medium from the well plate, added 293 T cells to the mixture of vectors and X-tremegene HP, cultured the mixtures at 37 °C with 5% CO2, incubated them for 5–6 h and supplemented them with 200 μl complete medium containing 10% fetal bovine serum (Vian-Saga, Shanghai, China) to ensure that each culture well contained 500 μl medium. The pGL3-basic vector without an insert sequence was used as a negative control. Luciferase activity was detected 48 h after transfection. We used the Dual-Luciferase Reporter Assay System (Promega) to measure the activity of the Firefly luciferase gene and the Renilla luciferase gene. For each constructed vector, independent triplicate experiments were performed.

Statistical analysis

Data were entered using EpiData 3.1 (EpiData Association, Denmark) and analyzed using SPSS version 25.0 (SPSS Inc., Illinois, USA). Student’s t-test (for continuous variables) and the χ2-test (for categorical variables) were used to analyze the differences in demographic variables and risk factors between cases and controls. The logistic regression model was used to estimate the effects of SNPs on susceptibility to COPD and PTB by calculating the odds ratio (OR) and 95% confidence interval (CI). We adjusted for age, sex, smoking and drinking to control for potential confounding factors. The significance level was defined as 0.05 in the present study. The Bonferroni correction was used to adjust the test level for multiple comparisons (0.05/5 = 0.01).

Results

General characteristics of study subjects

The basic characteristics of the cases and controls are listed in Table 1. The COPD case group consisted of 131 males and 21 females, and the PTB case group consisted of 1181 males and 420 females, while the control group consisted of 1272 males and 455 females. The distribution of ages was significantly different between the controls and the COPD group (t = 24.92, P < 0.001) or the PTB group (t = 4.84, P < 0.001). The sex distribution was different between the controls and the COPD group (χ2 = 11.60, P = 0.001). Tobacco smoking and alcohol drinking were also related to COPD or PTB (Table 1). Thus, we adjusted for age, sex, smoking and drinking when analyzing the effect of TLR4 SNPs.

Table 1.

Basic characteristics of cases and controls

Variables Control (n = 1727) COPD (n = 152) PTB (n = 1601) t/χ 2 COPD P COPD t/χ 2 PTB P PTB
Age (years)
 Mean(±SD) 55.03(±17.70) 75.97(±8.93) 52.06(±17.71) 24.92 < 0.001a 4.84 < 0.001a
Sex [n(%)] 11.60 0.001b 0.01 0.941b
 Male 1272 (73.7) 131 (86.2) 1181 (73.8)
 Female 455 (26.3) 21 (13.8) 420 (26.2)
Smoking [n(%)] 34.88 < 0.001b 88.01 < 0.001b
 Never 1101 (63.8) 60 (39.5) 762 (47.6)
 Ever 626 (36.2) 92 (60.5) 839 (52.4)
Drinking [n(%)] 0.01 0.932b 8.94 0.003b
 Never 1267 (73.4) 112 (73.7) 1246 (77.8)
 Ever 460 (26.6) 40 (26.3) 355 (22.2)
Open in a new tab

aStudent’s t-test; bχ2 test

Genetic variations of TLR4 on the risk of COPD and PTB

Five SNPs were all in Hardy-Weinberg equilibrium in the control group (P = 0.12 for rs10759932, P = 0.07 for rs2737190, P = 0.57 for rs7873784, P = 0.94 for rs11536889, and P = 0.47 for rs10983755). As listed in Table 2, after the Bonferroni correction, the genetic polymorphisms of five SNPs were all significantly associated with the susceptibility to COPD, while rs10759932 and rs2737190 were also associated with the risk of PTB. Compared with rs10759932-TT, individuals carrying TC (OR: 0.42, 95% CI: 0.28–0.64) or CC (OR: 0.24, 95% CI: 0.09–0.63) had a significantly reduced risk of COPD. However, TC (OR: 1.28, 95% CI: 1.11–1.49) or CC (OR: 1.26, 95% CI: 0.98–1.62) carriers had an increased risk of PTB. The OR (95% CI) for allele rs10759932-C was 0.45 (0.32–0.62) for COPD and 1.18 (1.07–1.32) for PTB. For rs2737190, the heterozygous AG was related to a decreased risk of COPD (OR: 0.32, 95% CI: 0.21–0.49) and an increased risk of PTB (OR: 1.30, 95% CI: 1.11–1.52). However, the effect of the rs2737190-GG genotype was significant only for COPD.

Table 2.

Genotype distributions of five SNPs between cases and controls

Gene SNPs Control, n(%) COPD, n(%) PTB, n(%) ORCOPD(95% CI)a P COPD ORPTB(95% CI)a P PTB
TLR4 rs10759932c
 TT 885 (51.6) 107 (72.8) 722 (45.7) 1 1
 TC 675 (39.4) 35 (23.8) 697 (44.1) 0.42 (0.28–0.64) < 0.001b 1.28 (1.11–1.49) 0.001b
 CC 154 (9.0) 5 (3.4) 161 (10.2) 0.24 (0.09–0.63) 0.004b 1.26 (0.98–1.62) 0.068
 T 2445 (71.3) 249 (84.7) 2141 (67.8) 1 1
 C 983 (28.7) 45 (15.3) 1019 (32.2) 0.45 (0.32–0.62) < 0.001b 1.18 (1.07–1.32) 0.002b
rs2737190c
 AA 630 (37.0) 91 (63.2) 518 (32.6) 1 1
 AG 781 (45.9) 34 (23.6) 840 (52.9) 0.32 (0.21–0.49) < 0.001b 1.30 (1.11–1.52) 0.001b
 GG 291 (17.1) 19 (13.2) 231 (14.5) 0.42 (0.24–0.72) 0.002b 0.94 (0.76–1.16) 0.563
 A 2041 (60.0) 216 (75.0) 1876 (59.0) 1 1
 G 1363 (40.0) 72 (25.0) 1302 (41.0) 0.50 (0.38–0.66) < 0.001b 1.04 (0.94–1.15) 0.443
rs7873784c
 GG 1426 (83.3) 105 (72.9) 1310 (83.1) 1 1
 GC 275 (16.1) 33 (22.9) 256 (16.2) 1.55 (1.00–2.42) 0.052 1.02 (0.84–1.23) 0.860
 CC 11 (0.6) 6 (4.2) 11 (0.7) 16.72 (4.29–65.12) < 0.001b 1.27 (0.54–3.00) 0.591
 G 3127 (91.3) 243 (84.4) 2876 (91.2) 1 1
 C 297 (8.7) 45 (15.6) 278 (8.8) 1.95 (1.39–2.74) < 0.001b 1.02 (0.86–1.21) 0.841
rs11536889c
 GG 1013 (59.0) 47 (31.1) 953 (60.2) 1 1
 GC 611 (35.6) 67 (44.4) 535 (33.8) 2.68 (1.78–4.05) < 0.001b 0.97 (0.84–1.13) 0.713
 CC 93 (5.4) 37 (24.5) 94 (5.9) 8.65 (5.04–14.82) < 0.001b 1.10 (0.81–1.49) 0.559
 G 2637 (76.8) 161 (53.3) 2441 (77.1) 1 1
 C 797 (23.2) 141 (46.7) 723 (22.9) 2.90 (2.28–3.68) < 0.001b 0.98 (0.87–1.10) 0.730
rs10983755c
 GG 904 (52.5) 51 (33.8) 806 (50.7) 1 1
 GA 679 (39.4) 70 (46.4) 644 (40.5) 1.90 (1.28–2.82) 0.002b 1.07 (0.92–1.24) 0.366
 AA 139 (8.1) 30 (19.9) 139 (8.7) 4.27 (2.49–7.31) < 0.001b 1.09 (0.84–1.41) 0.533
 G 2487 (72.2) 172 (57.0) 2256 (71.0) 1 1
 A 957 (27.8) 130 (43.0) 922 (29.0) 1.96 (1.55–2.50) < 0.001b 1.06 (0.95–1.18) 0.270
Open in a new tab

aOR odds ratio, CI confidence interval; adjusted for age, sex, smoking and drinking; bsignificant after the Bonferroni correction for multiple comparisons. cwith missing values

Functional analysis of genetic variations

As shown in Fig. 2, the mean (±SD) values of relative luciferase activity were 0.166 (±0.002) for pGL3-basic, 2.502 (±0.059) for pGL3-Wt, 1.466 (±0.051) for pGL3-Mut1 and 1.963 (±0.032) for pGL3-Mut2. Compared with pGL3-Wt, the relative luciferase activity was significantly reduced in both pGL3-Mut1 (t = 30.78, P = 0.001) and pGL3-Mut2 (t = 25.72, P = 0.001), indicating a potential role of genetic variations of TLR4 rs10759932 (− 1309 T/C) and rs2737190 (− 2272 A/G) in regulating gene expression.

Fig. 2.

Fig. 2

Open in a new tab

The relative luciferase activity of recombinant vectors. pGL3-basic: vector without an insert sequence; pGL3-Wt: − 1309 T and − 2272 A; pGL3-Mut1: − 1309 C and − 2272 A; pGL3-Mut2: − 1309 T and − 2272 G

Discussion

COPD is emerging as the third largest cause of human mortality worldwide, and there is growing evidence for comorbidity between COPD and TB, the leading cause of death globally due to respiratory infection [17]. COPD and TB share a number of common risk factors, including innate immunity-related genetic factors. In the present study, we compared the role of genetic variations of the TLR4 gene in the susceptibility to COPD and PTB. We observed that the genetic polymorphisms of rs10759932 and rs2737190 were significantly associated with both COPD and PTB, but with inverse effects. Dual-luciferase reporter vectors suggested the potential function of these two SNPs regulating the transcription activity of the TLR4 gene.

TLR4 is a pattern recognition receptor that participates in both innate and adaptive immunity. TLR4 is located on the surface of monocytes and macrophages and transmits activation signals after lipopolysaccharide (LPS) recognition, induces the expression of proinflammatory cytokines, such as IL-1, myeloid differentiation factor 88 (MyD88) and TNF-α, and forms receptor complexes, resulting in the activation of NF-κB and its translocation into the nucleus, which mediates inflammatory responses and adaptive immune responses [21]. TLR4 plays an important role in lung structure maintenance and smoking-induced emphysema and stimulates low-grade activation of the innate immune system, which is required for lung structural stability [22–24]. Previous studies have demonstrated that the expression of TLR4 on the surface of peripheral blood mononuclear cells and the concentrations of TNF-α, IL-6 and IL-8 in the serum of COPD patients were all significantly increased and positively correlated [25–27]. TLR4 influences the expression of inflammatory cytokines and chemokines, such as TNF-α, IL-1, IL-6 and IL-8, and these cytokines and chemokines interact with each other, which in turn regulate the expression of TLR4 in the airway of patients with COPD [25–27]. Speletas et al. investigated common TLR polymorphisms (TLR2-R753Q, TLR4-D299G and TLR4-T399I) in a group of heavy smokers (> 20 pack years). The presence of the TLR4-T399I polymorphism was associated with a 2.4-fold increased risk for COPD development, but not with the disease stage or frequency of exacerbations [28]. A study in Germany observed that the TLR4-D299G polymorphism was related to COPD [29]. In our study, five SNPs in the TLR4 gene were all significantly associated with the risk of COPD, indicating its critical role in the development of COPD in the Chinese population.

It is estimated that approximately one third of the global population has been infected with MTB, but only 5–10% of these latently infected individuals eventually develop active TB, which may be attributed to different individual immunity [30, 31]. When MTB invades the host, TLR4 can recognize LPS, triggering the adaptor molecule MyD88 and other signaling pathways and initiating innate host defense against MTB [32, 33]. A study with mice found that mice with TLR4 were all alive at week 15 after intranasal inoculation with an MTB suspension, whereas 7 of 12 TLR4-deficient mice died [34]. The bacterial load of TLR4-deficient mice was 3-fold higher than that of mice with TLR4, and the levels of cytokines in TLR4-deficient mice were significantly decreased [34]. In the present study, we genotyped five functional SNPs in the TLR4 gene, and only rs10759932 and rs2737190 were associated with PTB. Moreover, the effect of these two SNPs on the risk of COPD and PTB was inverse. This may be attributed to the dual role of the inflammatory response. On the one hand, inflammatory mediators directly or indirectly cause damage to tissues and cells. For example, the TLR4 signaling pathway mediates inflammation after ischemia-reperfusion and leads to tissue damage [35, 36]. On the other hand, it dilutes, kills and surrounds damage factors through inflammatory hyperemia and exudation reactions, and repairs and heals the damaged tissue through the regeneration of parenchymal and mesenchymal cells. Jiang et al. reported that the interaction between the endogenous matrix component hyaluronic acid and TLR4 can trigger an inflammatory response, maintain structural cellular integrity, and promote the recovery of tissue damage [37, 38].

In this study, we constructed dual-luciferase reporter vectors expressing different genotypes and transfected them into the human HEK 293 T cell line to explore the effects of SNPs on the TLR4 gene. Our results showed that rs10759932-C (vs. T) and rs2737190-G (vs. A) can decrease the promoter activity of the TLR4 gene. The mutations of these two loci not only weaken the capacity of the immune system to recognize MTB but also reduce the production and release of proinflammatory cytokines, resulting in an increased risk of PTB. In COPD, the excessive expression of proinflammatory cytokines damages lung tissue and cells beyond the tolerance of the body during the chronic inflammatory process, leading to various combinations of bronchitis, emphysema and pulmonary fibrosis, which in turn aggravate the condition of COPD patients. This may partly explain the reduced risk of COPD by mutations in these two loci.

There were several limitations in this study. First, we only analyzed five SNPs in the TLR4 gene, and other immune-related genes were not considered. Second, although the dual-luciferase reporter vectors were used to estimate the altered transcriptional activity of the TLR4 gene due to rs10759932-C and rs2737190-G, the affected transcription factors were unclear. The altered TLR4 protein and downstream cytokines need to be measured in future studies. Third, there is a complex interrelationship between COPD and PTB, one of which can serve as an independent risk factor for the other [16, 17]. We investigated the history of TB among COPD cases. However, we do not know the proportion of COPD among PTB cases because respiratory function tests were not routinely performed for suspected TB cases. Therefore, the concomitance of both diseases may have been an important confounding factor when we analyzed the effects of TLR4 SNPs. Fourth, we only explored the functional effects of TLR4 rs10759932 (− 1309 T/C) and rs2737190 (− 2272 A/G), which were related to both COPD and PTB. The effects of the other three SNPs on the transcriptional activity of TLR4 were unclear.

In conclusion, genetic polymorphisms of rs10759932 and rs2737190 in TLR4 are significantly related to both COPD and PTB but have inverse effects. The altered transcription activity caused by mutations in these two loci may partly explain the observed relationship. More work is necessary to identify specific causative variants underlying the observed associations. Further translational studies are warranted to delineate the molecular events behind these associations.

Supplementary information

12890_2019_939_MOESM1_ESM.doc (30.5KB, doc)

Additional file 1 Table S1. Information on five SNPs in the TLR4 gene.

12890_2019_939_MOESM2_ESM.doc (31.5KB, doc)

Additional file 2 Table S2. Primers and probes designed for genotyping.

Abbreviations

CI

Confidence interval

COPD

Chronic obstructive pulmonary disease

DAMPs

Damage-associated molecular pattern molecules

LPS

Lipopolysaccharide

MTB

Mycobacterium tuberculosis

MyD88

Myeloid differentiation factor 88

OR

Odds ratio

PAMPs

Pathogen-associated molecular pattern molecules

PTB

Pulmonary tuberculosis

SNP

Single nucleotide polymorphism

TB

Tuberculosis

TLR

Toll-like receptor

Authors’ contributions

ZL and JW conceived, initiated, and led the study. ZL, XM, QL, HS, BH, PS, QZ, ZL and JW collected and analyzed the data with input from all the authors. ZL and JW prepared the manuscript. All authors contributed to data analysis, drafted and revised the paper, and agreed to be accountable for all aspects of the work. All authors reviewed and approved the manuscript.

Funding

This work was supported by the National Key R&D Program of China (2017YFC0907000), National Natural Science Foundation of China (81473027, 81973103), Social Development Project in Jiangsu Province (SBE2016740780) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

This study was approved by the ethics committee of Nanjing Medical University. Inform consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Zhongqi Li and Xuhua Mao contributed equally to this work.

Contributor Information

Zhongqi Li, Email: 915305119@qq.com.

Xuhua Mao, Email: jsyxmao@163.com.

Qiao Liu, Email: liuqiaonjmu@163.com.

Huan Song, Email: 1416639054@qq.com.

Biyu He, Email: 1747735557@qq.com.

Peiyi Shi, Email: 504915911@qq.com.

Qun Zhang, Email: lucyqzhang@126.com.

Xiaona Li, Email: 286696026@qq.com.

Jianming Wang, Phone: 86-25-86868438, Email: jmwang@njmu.edu.cn.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s12890-019-0939-y.

References

  • 1.Inghammar M, Ekbom A, Engstrom G, Ljungberg B, Romanus V, Lofdahl CG, Egesten A. COPD and the risk of tuberculosis--a population-based cohort study. PLoS One. 2010;5(4):e10138. doi: 10.1371/journal.pone.0010138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. doi: 10.1016/j.ccm.2013.10.004. [DOI] [PubMed] [Google Scholar]
  • 3.McDonald CF, Khor Y. Advances in chronic obstructive pulmonary disease. Intern Med J. 2013;43(8):854–862. doi: 10.1111/imj.12219. [DOI] [PubMed] [Google Scholar]
  • 4.Balkissoon R, Lommatzsch S, Carolan B, Make B. Chronic obstructive pulmonary disease: a concise review. Med Clin North Am. 2011;95(6):1125–1141. doi: 10.1016/j.mcna.2011.08.009. [DOI] [PubMed] [Google Scholar]
  • 5.Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, Cong S, Juan J, Fan J, Lu K, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi: 10.1016/S2213-2600(18)30103-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lee SJ, Kim SW, Kong KA, Ryu YJ, Lee JH, Chang JH. Risk factors for chronic obstructive pulmonary disease among never-smokers in Korea. Int J Chron Obstruct Pulmon Dis. 2015;10(1):497–506. doi: 10.2147/COPD.S77662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zhou Y, Chen R. Risk factors and intervention for chronic obstructive pulmonary disease in China. Respirology. 2013;18(S3):4–9. doi: 10.1111/resp.12190. [DOI] [PubMed] [Google Scholar]
  • 8.Zhang Q, Wang M, Li X, Wang H, Wang J. Do symptom-based questions help screen COPD among Chinese populations? Sci Rep. 2016;6:30419. doi: 10.1038/srep30419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sgaragli G, Frosini M. Human tuberculosis I. epidemiology, diagnosis and pathogenetic mechanisms. Curr Med Chem. 2016;23(25):2836–2873. doi: 10.2174/0929867323666160607222854. [DOI] [PubMed] [Google Scholar]
  • 10.Lin HH, Murray M, Cohen T, Colijn C, Ezzati M. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet. 2008;372(9648):1473–1483. doi: 10.1016/S0140-6736(08)61345-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Metcalfe HJ, Lea S, Hughes D, Khalaf R, Abbott-Banner K, Singh D. Effects of cigarette smoke on toll-like receptor (TLR) activation of chronic obstructive pulmonary disease (COPD) macrophages. Clin Exp Immunol. 2014;176(3):461–472. doi: 10.1111/cei.12289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Berrington WR, Hawn TR. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol Rev. 2007;219:167–186. doi: 10.1111/j.1600-065X.2007.00545.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vijay K. Toll-like receptors in immunity and inflammatory diseases: past, present, and future. Int Immunopharmacol. 2018;59:391–412. doi: 10.1016/j.intimp.2018.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Apostolou A, Kerenidi T, Michopoulos A, Gourgoulianis KI, Noutsias M, Germenis AE, Speletas M. Association between TLR2/TLR4 gene polymorphisms and COPD phenotype in a Greek cohort. Herz. 2017;42(8):752–757. doi: 10.1007/s00059-016-4510-9. [DOI] [PubMed] [Google Scholar]
  • 15.Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediat Inflamm. 2016;2016(7):6978936. doi: 10.1155/2016/6978936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jain NK. Chronic obstructive pulmonary disease and tuberculosis. Lung India. 2017;34(5):468–469. doi: 10.4103/lungindia.lungindia_183_17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.O'Toole RF, Shukla SD, Walters EH. TB meets COPD: an emerging global co-morbidity in human lung disease. Tuberculosis (Edinb) 2015;95(6):659–663. doi: 10.1016/j.tube.2015.08.005. [DOI] [PubMed] [Google Scholar]
  • 18.Dai Y, Zhang Z, Xu L, Shang Y, Lu R, Chen J. Genetic polymorphisms of IL17A, TLR4 and P2RX7 and associations with the risk of chronic obstructive pulmonary disease. Mutat Res. 2018;829-830:1–5. doi: 10.1016/j.mrgentox.2018.03.005. [DOI] [PubMed] [Google Scholar]
  • 19.Wang M, Xu G, Lu L, Xu K, Chen Y, Pan H, Burstrom B, Burstrom K, Wang J. Genetic polymorphisms of IL-17A, IL-17F, TLR4 and miR-146a in association with the risk of pulmonary tuberculosis. Sci Rep. 2016;6:28586. doi: 10.1038/srep28586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805. [DOI] [PubMed] [Google Scholar]
  • 21.Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820. doi: 10.1016/j.cell.2010.01.022. [DOI] [PubMed] [Google Scholar]
  • 22.Maes T, Bracke KR, Vermaelen KY, Demedts IK, Joos GF, Pauwels RA, Brusselle GG. Murine TLR4 is implicated in cigarette smoke-induced pulmonary inflammation. Int Arch Allergy Immunol. 2006;141(4):354–368. doi: 10.1159/000095462. [DOI] [PubMed] [Google Scholar]
  • 23.Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest. 2008;118(2):394–402. doi: 10.1172/JCI31811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang X, Shan P, Jiang G, Cohn L, Lee PJ. Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest. 2006;116(11):3050–3059. doi: 10.1172/JCI28139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Budulac SE, Boezen HM, Hiemstra PS, Lapperre TS, Vonk JM, Timens W, Postma DS, Group Gs Toll-like receptor (TLR2 and TLR4) polymorphisms and chronic obstructive pulmonary disease. PLoS One. 2012;7(8):e43124. doi: 10.1371/journal.pone.0043124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bezemer GF, Sagar S, van Bergenhenegouwen J, Georgiou NA, Garssen J, Kraneveld AD, Folkerts G. Dual role of toll-like receptors in asthma and chronic obstructive pulmonary disease. Pharmacol Rev. 2012;64(2):337–358. doi: 10.1124/pr.111.004622. [DOI] [PubMed] [Google Scholar]
  • 27.Tohno M, Shimazu T, Aso H, Kawai Y, Saito T, Kitazawa H. Molecular cloning and functional characterization of porcine MyD88 essential for TLR signaling. Cell Mol Immunol. 2007;4(5):369–376. [PubMed] [Google Scholar]
  • 28.Speletas M, Merentiti V, Kostikas K, Liadaki K, Minas M, Gourgoulianis K, Germenis AE. Association of TLR4-T399I polymorphism with chronic obstructive pulmonary disease in smokers. Clin Dev Immunol. 2009;2009:260286. doi: 10.1155/2009/260286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rohde G, Klein W, Arinir U, Hagedorn M, Duerig N, T Bauer T, Gillissen A, Schultze-Werninghaus G, T Epplen J. Association of the ASP299GLY TLR4 polymorphism with COPD. Respir Med. 2006;100(5):892–896. doi: 10.1016/j.rmed.2005.08.018. [DOI] [PubMed] [Google Scholar]
  • 30.Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, Maeurer M, Zumla A. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFalpha drugs. Curr Opin Pulm Med. 2012;18(3):233–240. doi: 10.1097/MCP.0b013e328351f9d6. [DOI] [PubMed] [Google Scholar]
  • 31.Monin L, Khader SA. Chemokines in tuberculosis: the good, the bad and the ugly. Semin Immunol. 2014;26(6):552–558. doi: 10.1016/j.smim.2014.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Biyikli OO, Baysak A, Ece G, Oz AT, Ozhan MH, Berdeli A. Role of toll-like receptors in tuberculosis infection. Jundishapur J Microbiol. 2016;9(10):e20224. doi: 10.5812/jjm.20224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011(1):405310. doi: 10.1155/2011/405310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Branger J, Leemans JC, Florquin S, Weijer S, Speelman P, Van Der Poll T. Toll-like receptor 4 plays a protective role in pulmonary tuberculosis in mice. Int Immunol. 2004;16(3):509–516. doi: 10.1093/intimm/dxh052. [DOI] [PubMed] [Google Scholar]
  • 35.Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007;115(12):1599–1608. doi: 10.1161/CIRCULATIONAHA.106.603431. [DOI] [PubMed] [Google Scholar]
  • 36.Kaczorowski DJ, Nakao A, Vallabhaneni R, Mollen KP, Sugimoto R, Kohmoto J, Zuckerbraun BS, McCurry KR, Billiar TR. Mechanisms of toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation. 2009;87(10):1455–1463. doi: 10.1097/TP.0b013e3181a36e5e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–1179. doi: 10.1038/nm1315. [DOI] [PubMed] [Google Scholar]
  • 38.Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435–461. doi: 10.1146/annurev.cellbio.23.090506.123337. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12890_2019_939_MOESM1_ESM.doc (30.5KB, doc)

Additional file 1 Table S1. Information on five SNPs in the TLR4 gene.

12890_2019_939_MOESM2_ESM.doc (31.5KB, doc)

Additional file 2 Table S2. Primers and probes designed for genotyping.

Data Availability Statement

All data generated or analyzed during this study are included in this published article.

Articles from BMC Pulmonary Medicine are provided here courtesy of BMC

RESOURCES